A Retrospective Review - Anti-HLA Antibodies

Status Withdrawn

Clinical Trial Summary

Transplant rejection following organ transplant occurs because the recipient's immune system attacks the transplanted organ. The recipients immune system recognizes the transplanted organ as foreign tissue and attempts to destroy it in the similar way that it attempts to destroy infectious agents such as bacteria and viruses. The human leukocyte antigen (HLA) system is a set of genes that is responsible for controlling an individuals' ability to tell the difference between an infectious agent and self tissue.

Differences in HLA genes between donors and recipients play a major part in influencing the rejection or acceptance of foreign tissue (i.e. transplanted organs). Due to time limitations in heart transplantation, HLA matching is not considered. It is unclear how individual HLA differences affect the recovery and expected lifespan of pediatric heart transplant recipients.

This study is designed to look at the donor-recipient matching and mismatching to determine if mismatching leads to more complications, shorter graft survival and, therefore, increased risk of death following pediatric heart transplantation.

Clinical Trial Description

It is generally thought that immunologic mismatching in solid organ transplant will lead to increased rates of graft failure due to acute rejection in the short term and chronic rejection, or coronary vasculopathy in the longterm. Many studies in renal, pancreas and lung transplantation suggest favorable outcomes when HLA matching occurs and unfavorable outcomes when HLA mismatching occurs and circulating donor-specific antibodies are produced.

However, in heart transplantation this association is less clear. Advances in recognition and identification of HLA antibodies have resulted in more specific information regarding HLA mismatching and outcomes. This study is aimed at analyzing outcomes in pediatric heart transplant based on recipient-donor HLA incompatibility and the post-transplant production of donor-specific HLA antibodies.

Hypothesis:

1. HLA systems' genes class I & II matching results in a survival/rejection benefit in pediatric heart transplant recipients.

2. Mismatched transplants with donor-specific HLA antibodies have decreased overall survival.

A Multivariate Analysis of data will be performed by both Emory and Children's investigators and research support staff. ;

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Congenital Disorders

Clinical Trial Details

NCT number	NCT00460824
Study type	Observational
Source	Emory University
Contact
Status	Withdrawn
Phase	N/A
Start date	July 1988

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04405700` - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Not yet recruiting	`NCT03291678` - Impact of Percutaneous Laparoscopic Assisted Internal Ring Ligation During Lap Orchiopexy	N/A
Completed	`NCT00489788` - Predictors for Pulmonary Valve Replacement - Anatomic and Hemodynamic Using MRI	N/A
Terminated	`NCT00268060` - Infant Medical Records: Case Report Proposal	N/A
Not yet recruiting	`NCT05955794` - Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes	N/A
Completed	`NCT00257517` - Multisite Feeding Study: Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle	N/A
Completed	`NCT00478296` - Pulmonary Hypertension in Trisomy 21 Patients	N/A
Completed	`NCT04556487` - Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Terminated	`NCT00261989` - Pulse Oximetry Readings and Hourly Variation in Oximetry Readings With CHD	N/A
Completed	`NCT00211081` - Spironolactone in Patients With Single Ventricle Heart	N/A
Terminated	`NCT00268099` - Optimal Timing for Repair of Right-to-Left Shunt Lesions	N/A
Active, not recruiting	`NCT05752019` - TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era
Completed	`NCT00490295` - Biomarkers for Detection of Brain Ischemia	N/A
Terminated	`NCT00327899` - Home Inotropic Therapy in Children	N/A
Terminated	`NCT00229905` - Child With Anomalous Drainage of IVC to Left Atrium	N/A
Completed	`NCT00277901` - MRI Assessment of RV Function: Patients With TOF or Aortic Coarctation	N/A
Terminated	`NCT00366314` - Frequency of Accessing Central Lines for Blood Samples	N/A
Terminated	`NCT00268034` - Left Ventricular Aneurysms in Children	N/A
Completed	`NCT00366847` - Computer Modeling of Congenital Heart Disease	N/A
Recruiting	`NCT05749419` - Vaccinations and People With Disabilities

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.